Saturday, March 28, 2026

Watchman FLX Matches DOACs in AF but Raises Questions

In the CHAMPION-AF trial, Watchman FLX LAAO was noninferior to DOACs for the composite of CV death, stroke, or systemic embolism at 3 years in AF patients eligible for long-term anticoagulation (5.7% vs 4.8%; difference 0.9%). It also cut non-procedure-related bleeding (10.9% vs 19.0%), though overall ISTH major bleeding rates were similar when including periprocedural events. Results were presented at ACC.26 and published in NEJM.




Trial details

The study randomized 3,000 patients (mean CHA2DS2-VASc 3.5) at 141 sites to Watchman FLX or DOAC. Successful implant occurred in 92.5%, with effective closure in 98.6% at 4 months. Post-implant antithrombotics transitioned to single antiplatelet therapy after 3 months. DOAC adherence was 87%, with 13.7% crossover to LAAO.

Safety and efficacy

Non-procedure-related bleeding favored LAAO, but ischemic stroke or systemic embolism was numerically higher (3.2% vs 2.2%). CV death was identical (2.7%). Device issues included pericardial effusion (0.7%), DRT (4.8%), and procedure-related serious events (2.3%). A net clinical benefit endpoint (including non-procedure bleeding) showed superiority for LAAO (15.1% vs 21.8%).

Clinical debate

Experts debated the wide noninferiority margin (4.8%), low event rates below powering assumptions, more ischemic strokes in LAAO, and selective bleeding endpoint. It contrasts with CLOSURE-AF, which favored medical therapy in high-bleed-risk patients. LAAO may suit shared decision-making for suitable AF patients, but not as first-line replacement for DOACs in all. Upcoming CATALYST and 5-year CHAMPION-AF data will add clarity.

Catheter-Directed Therapy Bests Anticoagulation in Intermediate-Risk PE

In the HI-PEITHO trial, ultrasound-facilitated catheter-directed fibrinolysis plus anticoagulation cut the risk of PE-related death, cardiorespiratory decompensation, or recurrence by 61% at 7 days compared with anticoagulation alone in acute intermediate-risk PE. The benefit was driven mainly by fewer cases of decompensation or collapse, without excess bleeding. Results were presented at ACC.26 and published in NEJM.

Key results

The trial randomized 544 patients from 59 sites with confirmed intermediate-risk PE, defined by RV dysfunction, elevated troponin, and signs of cardiorespiratory distress. Intervention patients received EkoSonic thrombolysis (mean alteplase dose 8-17 mg) plus heparin within 2 hours. The primary composite endpoint at 7 days was 4.0% vs 10.3% (RR 0.4; P=0.005), with a number needed to treat of 16.

Safety profile

No significant differences emerged in major bleeding by ISTH or GUSTO criteria at 72 hours, 7 days, or 30 days, and there were no intracranial bleeds. All-cause mortality was low and similar at 30 days (1.8% intervention vs 1.1% control). Escalation to rescue therapy was also less frequent in the intervention arm.

Clinical implications

Experts said the results support catheter-directed therapy for select intermediate-high-risk patients, like those in category D of the 2026 PE guidelines (incipient failure with hypotension or normotensive shock). Caution is advised against broad extrapolation beyond this enriched cohort, which excluded many screened patients. The trial builds on PEITHO by showing efficacy with lower bleeding risk than systemic lysis.

Mechanical Circulatory Support Doesn’t Reduce Infarct Size in STEMI without shock

In the STEMI Door-to-Unload trial, use of Impella CP failed to reduce infarct size in patients with anterior STEMI without cardiogenic shock, and it increased the risk of major bleeding and vascular complications compared with PCI alone. The findings were presented at ACC.26 and published simultaneously in JACC.

Trial results

The randomized study included 527 patients with anterior STEMI and no shock, comparing 30 minutes of LV unloading before PCI with PCI alone. The primary endpoint—infarct size normalized to LV mass on cardiac MRI—was not significantly different between groups. There was also no meaningful improvement in secondary clinical outcomes.

Safety signal

The main downside was safety: major bleeding and major vascular complications were higher with Impella than with PCI alone. Device-related access-site bleeding accounted for much of the excess risk. Investigators said the results did not meet an acceptable performance threshold for safety.

Clinical takeaway

Experts emphasized that these findings apply to patients without shock, not to patients with cardiogenic shock, where Impella remains a different clinical tool. In this STEMI population, the risk-benefit balance does not support routine use of Impella to reduce infarct size. The study adds to a long list of therapies that looked promising mechanistically but did not translate into clinical benefit.

Friday, March 27, 2026

2026 AHA/ACC Guideline on Pulmonary Embolism: Clinical Classification and Management

Pulmonary embolism management just got a major upgrade with the first dedicated AHA/ACC guideline, introducing a practical five-category classification system that guides everything from diagnosis to advanced therapies like mechanical thrombectomy and ECMO.


Background and Context

In February 2026, the American Heart Association (AHA) and American College of Cardiology (ACC) released their first-ever comprehensive guideline on acute pulmonary embolism (PE) in adults, developed jointly with ACCP, ACEP, CHEST, SCAI, SHM, SIR, SVM, and SVN. This landmark document replaces fragmented prior approaches with an evidence-based framework spanning diagnosis, risk stratification, anticoagulation, and invasive interventions across emergency, hospital, and outpatient settings.

The guideline's centerpiece is the new AHA/ACC PE Clinical Categories (A–E with subcategories), expanding beyond traditional low/intermediate/high-risk schemes to include asymptomatic/incidental PE (Category A) through hemodynamically unstable disease (Categories E1–E2). A novel "respiratory modifier" for Categories C–E recognizes severe PE with preserved systolic blood pressure but prominent respiratory failure, addressing a key real-world gap.

For full access, clinicians should bookmark the official JACC guideline publication and AHA/ACC summary tools, including Figure 1 illustrating the classification system.


Diagnostic Approach

For patients with suspected PE and pretest probability <50% (per Wells or Geneva scores), PE can often be ruled out without imaging using an age-adjusted D-dimer, the YEARS criteria, or both, reducing unnecessary CT exposure.

CT pulmonary angiography (CTPA) remains the gold standard for diagnosis when imaging is needed, but ventilation-perfusion (V/Q) SPECT is a strong alternative if CTPA is contraindicated (e.g., renal failure, contrast allergy).

Risk stratification integrates clinical scores like the simplified PESI (sPESI), biomarkers (troponin, BNP), imaging (RV/LV ratio, clot burden), lactate, cardiac index, and respiratory status to assign the A–E category.


Management by Clinical Category

The guideline tailors therapy to the five-category system, balancing anticoagulation, hospitalization needs, and advanced interventions:

Categories A–B (incidental PE or low-risk symptomatic PE):
Direct oral anticoagulants (DOACs) enable home treatment or early discharge in stable patients without RV dysfunction or other high-risk features. No routine thrombolysis or intervention needed.

Categories C1–E1 (intermediate-high to high-risk with stable BP):

Category E2 (refractory cardiogenic shock):
Extracorporeal membrane oxygenation (ECMO) is reasonable as rescue therapy alongside systemic thrombolysis or mechanical support.

Special situations:
IVC filters are reasonable for absolute anticoagulation contraindications (active bleed, recent neurosurgery). Long-term anticoagulation (>3–6 months) should weigh cancer status, provoked vs. unprovoked PE, recurrent risk, and bleeding potential.


Anticoagulation Details

Clinical ScenarioPreferred AgentKey Considerations
Outpatient/early discharge (A–B)DOAC (apixaban, rivaroxaban) Simpler, no lab monitoring; avoid in CrCl <30 mL/min
Hospitalized (C1–E1)LMWH > UFH LMWH preferred unless high bleed risk or renal failure
Cancer-associated PELMWH or DOAC Extended therapy often indicated
PregnancyLMWH onlyDOACs contraindicated

Advanced Therapies and Controversies

The guideline gives Class 2a recommendation for catheter-based recanalization (thrombolysis or thrombectomy) in E1 patients (hemodynamic instability despite fluids/pressors), reflecting growing data on reduced ICU stay and bleeding vs. systemic thrombolysis.

For normotensive RV failure (C2–D2), these therapies remain Class 2b (may be reasonable) due to inconsistent trial outcomes—multidisciplinary PE response teams (PERT) are strongly encouraged for case-by-case decisions.

ECMO gets Class 2b support for refractory shock (E2), ideally with rapid wean post-stabilization and anticoagulation.


Implementation in Practice

This guideline transforms PE care from a one-size-fits-all approach to category-specific pathways that match intervention intensity to clinical need. High-yield steps for implementation:

  1. Embed sPESI, age-adjusted D-dimer, and YEARS into ED triage protocols to reduce imaging.

  2. Form multidisciplinary PERTs for C2–E patients, linking cardiology, IR, CT surgery, hematology.

  3. Standardize anticoagulation with DOACs for A–B, LMWH for C–E1 per above table.

  4. Develop Category E escalation pathways with 24/7 access to cath lab thrombectomy and ECMO.

  5. Anticoagulation clinic follow-up with structured 3–6 month reassessment for extension.

Bookmark the AHA/ACC PE Guideline hub, JACC publication, and tools like MDCalc PE calculators for immediate reference.

Revisiting Key points from 2025 Adult Advanced Cardiac Life Support (ACLS) Update

Clinical takeaway: For most clinicians, the 2025 Adult Advanced Life Support (ALS) update will not change day‑to‑day practice, but it sharpens several key points around early chest compressions, practical defibrillation strategies, vascular access, and post–ROSC care that are worth deliberately incorporating into local protocols and education.


Background and context

At the end of 2025, the American Heart Association (AHA) CPR and ECC Guidelines were updated, revising and expanding the 2020 recommendations across adult, pediatric, and neonatal life support, systems of care, and education. The adult ALS section is detailed in “Part 9: Adult Advanced Life Support: 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” available in Circulation.

For bedside use and teaching, it is useful to bookmark the AHA landing page for the 2025 CPR and ECC Guidelines and the corresponding 2025 ALS algorithms. Clinicians who want the condensed summary can review the 2025 Guidelines Executive Summary.


Opioid overdose and initial actions

In suspected opioid‑associated arrest, the guidelines emphasize that clinicians should not delay CPR while naloxone is being obtained or administered. This is consistent with broader systems‑of‑care guidance summarized in the AHA’s overview of key 2025 CPR & ECC changes.

For protocol design, opioid overdose pathways and training materials should explicitly state “start chest compressions first” for unresponsive patients who are not breathing normally, with naloxone given in parallel when available. For a concise overview to share with teams, see the 2025 CPR and ECC guideline highlights (if updated document is available from AHA).


Chest compressions and mechanical CPR

The 2025 ALS guideline reaffirms that manual chest compressions remain the standard of care for out‑of‑hospital adult cardiac arrest. Mechanical compression devices are not recommended for routine use, and are reserved for select situations such as prolonged transport or procedures where manual CPR is impractical, as discussed in the Adult ALS section.

System‑level quality‑improvement efforts should therefore focus on manual CPR performance—rate, depth, minimal pauses—and timely defibrillation, guided by the AHA’s Adult Cardiac Arrest Algorithm. For a narrative discussion of these changes, see the review “Inside the 2025 CPR and ECC guideline updates from the AHA” in CHEST Physician.


Vascular access during ALS

The updated guidelines explicitly prefer intravenous (IV) access, usually peripheral, over intraosseous (IO) access for medication administration during adult ALS. IO access remains appropriate when IV access is delayed or not feasible, as outlined in Part 9: Adult Advanced Life Support.

When revising code protocols or resuscitation carts, IV‑first and IO‑second sequencing should be explicitly embedded in local ALS algorithms. Quick‑reference materials can also be aligned with the executive summary of the 2025 guidelines so that practice remains consistent across services.


Defibrillation and cardioversion specifics

The 2025 update gives clearer, practical guidance on energy selection and special defibrillation strategies:

  • For atrial fibrillation or flutter requiring electrical cardioversion, the guideline recommends starting synchronized cardioversion at 200 J biphasic, as specified in the Adult ALS guideline text.

  • For polymorphic ventricular tachycardia (pVT) with hemodynamic instability, clinicians should treat the rhythm as shockable and proceed with immediate unsynchronized defibrillation.

  • For refractory ventricular fibrillation, the routine use of vector‑change defibrillation and double‑sequential defibrillation is not recommended, given currently limited and mixed evidence, a point also highlighted in the 2025 key changes overview.

Teams that have adopted double‑sequential protocols should review these recommendations and consider revising local policies and teaching materials accordingly, keeping them aligned with the AHA defibrillation and ALS algorithms.


Point‑of‑care ultrasound (POCUS) during arrest

The guidelines acknowledge a role for point‑of‑care ultrasonography (POCUS) in cardiac arrest when performed by experienced operators and only if it does not interrupt chest compressions or delay critical interventions. This nuanced recommendation is discussed in the Adult ALS guideline article.

POCUS can help identify reversible causes such as tamponade, severe hypovolemia, or tension pneumothorax, and may help differentiate true PEA from pseudo‑PEA. To implement this safely, institutions should deliberately integrate POCUS into arrest simulations and team training, using the narrative guidance from the 2025 ALS guidelines and system‑of‑care recommendations in the executive summary.


Post resuscitation temperature management

For comatose adult survivors of cardiac arrest, the 2025 guidelines recommend active temperature control with a target of approximately 36 °C for at least 36 hours, rather than deep hypothermia. This approach is described in both the Adult ALS section and the Executive Summary of the 2025 Guidelines.

ICU protocols should therefore emphasize continuous temperature monitoring, device‑based control around 36 °C, avoidance of fever, and structured neuroprognostication—elements that can be aligned with the AHA’s broader post–cardiac arrest care guidance. Updating order sets with direct links to these documents can help standardize post‑ROSC care.


Education, training, and cognitive aids

The 2025 guidelines also underscore the importance of education, both for professionals and the public.

  • The AHA highlights that children around 12 years of age can learn effective CPR and AED use, supporting school‑based programs and the “CPR in schools” movement. For background on youth CPR capability, see this review of schoolchildren and life‑supporting first aid.

  • For clinicians, the guidelines endorse cognitive aids—such as checklists, visual algorithms, and smart‑device apps—during resuscitation, as noted in the 2025 guideline highlights and implementation discussions like the CHEST Physician summary of 2025 CPR and ECC updates.

  • In contrast, lay rescuers are encouraged to focus on simple, high‑yield actions—early CPR and rapid AED use—rather than complex apps or detailed checklists, consistent with the AHA’s public‑facing CPR & First Aid resources.

Hospitals can use these recommendations to justify widespread use of cognitive aids and resuscitation apps for professionals, while community programs emphasize hands‑only CPR and accessible AED training supported by AHA AED implementation materials.


Bringing it into your practice

Taken together, the 2025 Adult ALS changes are evolutionary rather than revolutionary, but they refine several high‑yield elements of resuscitation practice. Clinicians can quickly operationalize the update by emphasizing “CPR first” in opioid overdose, preferring manual compressions over routine mechanical devices, prioritizing IV over IO access, applying the updated defibrillation and cardioversion recommendations, using POCUS judiciously without interrupting compressions, targeting 36 °C for at least 36 hours post‑ROSC, and systematically integrating cognitive aids into professional resuscitation. For a single entry point to all official documents, keep the AHA 2025 CPR and ECC Guidelines portal readily available on your clinical devices.

Thursday, March 26, 2026

Benefits of Early SAVR for Asymptomatic Aortic Stenosis Persist a Decade On

Patients with asymptomatic severe aortic stenosis (AS) live longer and avoid more heart-failure hospitalizations when they choose early surgical aortic valve replacement (SAVR) instead of waiting for symptoms.

Why Early SAVR Wins Long-Term

Final 10-year results from the RECOVERY trial and NEJM publication show immediate SAVR slashed the composite of operative mortality or cardiovascular death from 24% (conservative care) to 3% (early surgery; HR 0.10). All-cause mortality dropped to 15% versus 32%, with zero operative deaths in either group. Benefits held steady over a median 12 years, yielding a number needed to treat of 6 to avert one CV death and 7 for any death.

RECOVERY Trial Essentials

The trial randomized 145 truly asymptomatic patients (mean age ~64 years) with very severe ASaortic valve area ≤ 0.75 cm² plus peak velocity ≥ 4.5 m/s or mean gradient ≥ 50 mm Hg—to early SAVR (within 2 months) or conservative care with AVR for symptoms, LVEF < 50%, or rapid progression. 85% of conservative patients eventually needed AVR (mostly SAVR), but faced higher CV and all-cause death plus 19% heart-failure hospitalizations (vs 0% early).

Fits With Broader Evidence

RECOVERY aligns with AVATAR, EARLY TAVR, and EVOLVED, all backing early intervention in asymptomatic severe AS. Its younger, low-comorbidity cohort with bicuspid valves and extreme gradients likely drove the stark survival gap. ESC and ACC/AHA guidelines endorse class IIa for early AVR in low-risk cases with peak velocity > 5.0 m/s, rapid change, or elevated BNP.

Shared Decision-Making Guide

Frame discussions around prosthetic valve risks (degeneration, thromboembolism, bleeding) versus irreversible LV damage from prolonged overload. Watchful waiting suits vigilant patients who report symptoms promptly; early SAVR/TAVR appeals to those prioritizing proven long-term gains. Trials like EASY-AS will refine for elderly, comorbid patients often undertreated today.

To-Do List in Office Visit for Patient with Asymptomatic Severe AS

Use this prioritized checklist for a practicing cardiologist seeing a patient like those in the RECOVERY trialasymptomatic, very severe AS (peak velocity ≥ 4.5 m/s, AVA ≤ 0.75 cm², mean gradient ≥ 50 mm Hg).

  • Confirm diagnosis via recent echo review: Verify severe AS criteria, assess LVEF ≥ 50%, check LV geometry, pulmonary pressures, and serial progression (e.g., Vmax increase ≥ 0.3-0.5 m/s/year).

  • Assess true asymptomatic status: Probe for subtle exertional dyspnea, fatigue, or reduced exercise tolerance using standardized questionnaire; review patient diary if available.

  • Order exercise stress test if not done: Look for valve-related symptoms, abnormal BP response (fall >10 mm Hg), or low exercise capacityclass I/IIa trigger for AVR per ESC/ACC guidelines.

  • Quantify risk markers: Measure BNP/NT-proBNP (elevated = class IIa for AVR); consider CT calcium score if low-gradient; evaluate coronary anatomy via CT angio or invasive if indicated.

  • Calculate surgical risk: Use STS score or EuroSCORE II; confirm low risk (<1-2% mortality) for class IIa early AVR recommendation if Vmax > 5.0 m/s.

  • Discuss RECOVERY evidence: Share 10-year data (3% vs 24% CV death with early SAVR); highlight NNT 6-7 and zero HF hospitalizations in early arm.

  • Engage in shared decision-making: Weigh early SAVR/TAVR benefits (survival, QOL) vs watchful waiting risks (sudden death, irreversible LV damage); address prosthesis durability, bleeding/anticoagulation.

  • Plan surveillance if deferring: Schedule echo every 6 months; symptom check-ins q3 months; educate on red flags (new dyspnea, syncope); immediate AVR if LVEF drops <50-60%.

  • Refer to Heart Team: Consult CT surgery, interventional, imaging for SAVR vs TAVR eligibility; document discussion in notes.

  • Follow up promptly: Book return in 4-6 weeks post-testing; update guidelines (e.g., 2025 ESC/EACTS, 2020/updated ACC/AHA).

Four-Biomarker Midlife CAD Prediction: Genomics + Lipids + Inflammation

A landmark UK Biobank study integrates genomics with lipid and inflammatory markers to predict coronary artery disease (CAD) risk more accurately in midlife.

Four-Biomarker Model

The approach combines coronary artery disease polygenic risk score (CAD PRS)—calculated from DNA analysis of hundreds of common genetic variants via blood, saliva, or cheek swab—LDL cholesterol (LDL-C), lipoprotein(a) (Lp(a)), and high-sensitivity C-reactive protein (hsCRP). In 215,695 adults aged 40-69 followed for 12 years, each elevated biomarker independently raised CAD hazard ratios: CAD PRS (1.79), LDL-C (1.60), Lp(a) (1.20), hsCRP (1.64). All four elevated together increased risk 4.65-fold.[pmc.ncbi.nlm.nih]​

Age and Sex Effects

Associations were stronger in younger individuals across all markers (P<0.0001) and for CAD PRS in men (HR 1.49 per SD) versus women (1.37; P-interaction ≤0.001). The model achieved a C-statistic of 0.753, surpassing pooled cohort equations (0.740), with 32% improved net reclassification.

Clinical Implications

A single midlife panel outperforms traditional calculators, especially for early prevention in younger adults. CAD PRS testing ($255 via Mass General Brigham) provides a one-time genetic snapshot in 3-4 weeks to triage high-risk patients for statins, Lp(a) therapies, or CCTA.​

Wednesday, March 25, 2026

Several Factors Linked to Subsequent Events After TIA, Minor Stroke

A new systematic review and meta-analysis published in Circulation identifies multiple factors—spanning demographics, medical history, and characteristics of the index event—that help predict long-term stroke risk following a transient ischemic attack (TIA) or minor stroke.

The investigation synthesized data from 28 cohort studies encompassing over 86,000 patients to estimate population attributable fractions (PAFs) and determine which variables most strongly influence future stroke events.

Among nonmodifiable traits, having a minor stroke rather than a TIA as the index event carried the largest population impact (PAF 28%). Modifiable contributors—hypertension, smoking, and specific stroke subtypes linked to cardio-embolism, large-artery atherosclerosis, and small-vessel disease—also emerged as key drivers (PAFs 11.1%–19.3%).

These findings highlight how targeted follow-up and aggressive secondary prevention strategies could be directed toward high-risk individuals. Given limited capacity to monitor all TIA or minor stroke patients, this approach helps identify those who would benefit most from intensified prevention.

Risk also increased with advancing age, male sex, atrial fibrillation, diabetes, and prior stroke/TIA, with adjusted hazard ratios ranging from 1.29 to 1.70. Additionally, markers at presentation—including an elevated ABCD2 score, DWI-positive lesions, and ischemic subtypes—proved prognostic for recurrence.

The study underscores the importance of precise diagnosis since misclassification of a minor stroke could affect management intensity. Quantifying risk through PAFs, rather than relying solely on qualitative assessments, provides actionable insights for clinical decision-making and resource allocation.

These findings reinforce that identifying high-risk subsets after TIA or minor stroke can refine clinical resources and improve long-term outcomes through better-tailored care.

Full study: Prognostic factors for long-term risk of stroke after transient ischemic attack or minor stroke.


Related coverage: Risk of Another Event Remains High Years After TIA, Minor Stroke.


Tuesday, March 24, 2026

LAA Closure vs. Medical Therapy: New Insights from CLOSURE-AF

For high-risk patients with Atrial Fibrillation (AFib), choosing the right stroke prevention strategy is a delicate balance. The recently published CLOSURE-AF trial in the New England Journal of Medicine provides critical clarity on whether Left Atrial Appendage (LAA) closure is a viable alternative to standard medical care for this specific group.

The Study at a Glance

The trial, detailed by the American College of Cardiology, followed 912 older patients (average age 78) who faced a high risk for both stroke and major bleeding. Participants were randomized to receive either a catheter-based LAA closure device or physician-directed medical therapy, which typically included direct oral anticoagulants.

Key Findings

  • Noninferiority Not Met: The study found that LAA closure was not noninferior to medical therapy regarding the composite endpoint of stroke, systemic embolism, or death.

  • Complication Risks: While the device was successfully implanted in 98% of cases, 6% of patients suffered periprocedural complications, including pericardial tamponade and major bleeding.

  • Standard of Care: The results suggest that for older, high-risk patients, individualized medical therapy remains the preferred standard over catheter-based interventions.

As noted by study authors, this vulnerable patient group is particularly prone to early complications, making the "theoretical promise" of the device difficult to realize in clinical practice.